• The latest solution to enable comprehensive genomic profiling of tumors will be presented at the annual meeting of the Association of Molecular Pathology
• Customer-led research and presentations at the conference will deliver the latest evidence and education in tumor profiling

SAN DIEGO, Nov. 19, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that it will release TruSight^™ Oncology 500 v2 (TSO 500 v2), a new version of its flagship cancer research assay to enable comprehensive genomic profiling (CGP). The assay is currently under development, with global release planned for mid-2025. Detailed plans for the product will be shared November 21 in a spotlight presentation at the annual meeting of the Association of Molecular Pathology (AMP) in Vancouver, British Columbia.

TSO 500 v2 assesses hundreds of genes across all variant classes, and immuno-oncology biomarkers, in a single assay from one sample, to facilitate therapy selection research.

Key features of TSO 500 v2 include:

• Faster turnaround time and reduced hands-on time
• Sensitive variant calling and improved coverage of difficult genomic regions
• Gold-standard Myriad^® Genomic Instability Score (GIS) to determine homologous recombination deficiency (HRD) status, included for all samples
• New kit configurations with 50% less packaging, 70% fewer tubes, and improved usability
• Automation methods available with flexible batch sizes
• Integrated and automated data analysis, from sequencer to insights supported with DRAGEN^™ secondary analysis and Illumina Connected Insights, or Velsera's Clinical Genomics Workspace (CGW)
• Broad platform compatibility

At AMP, several abstracts accepted for poster presentations will demonstrate preliminary analytical performance data and automation compatibility of TSO 500 v2. The studies support the assay's applications for clinical research in identifying rare genetic biomarkers and fusion biomarkers.

TSO 500 v2 early access customer response

Wei Song, MD, PhD, director of Clinical Genomics and Molecular Pathology at the University of California, San Diego, is an early access customer testing TSO 500 v2.

"We are excited to assess the new features of the TruSight Oncology 500 v2 tissue assay, such as the faster workflow, improved coverage, and lower DNA/RNA input levels," he said. "Such improvements are highly relevant to clinical research laboratories and can positively affect time to results, quality of results, and the processing of challenging tissue samples."

TruSight Oncology portfolio enables clinical research and in-vitro diagnostic CGP solutions

Illumina's oncology portfolio has evolved over time to fit customers' diverse needs for versatility and scalability. The TSO portfolio encompasses research-use-only (TSO 500 products) and in-vitro diagnostic (TSO Comprehensive) solutions across a range of low-, mid-, and high-throughput instrumentation. Illumina also announced today that TSO Comprehensive kits are now available to ship. In August, the company announced FDA approval of its TSO Comprehensive test and its first two companion diagnostic indications.

"In listening to our broad range of customers, we understand there are different needs for biomarker profiling, and Illumina has successfully introduced a continuum of solutions to address varying levels of need," said Traci Pawlowski, vice president of Clinical Solutions at Illumina.

CGP is a critical tool for identifying actionable alterations, including rare mutations, which enables precision medicine in accordance with professional guidelines. At AMP, several customer-led poster presentations will provide further evidence for the clinical utility of CGP and demonstrate its versatility in hospital and community oncology care settings.

Illumina will cohost a workshop with Bayer, featuring a panel discussion of key opinion leaders on the challenges and practice gaps in precision medicine implementation, and the coordination of a multidisciplinary team to ensure optimal biomarker detection and targeted therapy utilization.

For a list of Illumina workshops and presentations at AMP, visit the company's events page.

Use of forward-looking statements

This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) challenges inherent in developing and launching new products and services, including modifying and scaling manufacturing operations, and reliance on third-party suppliers for critical components; (ii) our ability to manufacture robust instrumentation and consumables; and (iii) the acceptance by customers of our newly launched products, which may or may not meet our and their expectations, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.

Contacts

Investors:
Salli Schwartz
858-291-6421
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media:
Christine Douglass
This email address is being protected from spambots. You need JavaScript enabled to view it.